Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03553433
Other study ID # DER-USZ-AAN-021
Secondary ID
Status Not yet recruiting
Phase Phase 4
First received
Last updated
Start date June 2018
Est. completion date June 2020

Study information

Verified date June 2018
Source University of Zurich
Contact Alexander Navarini, MD PhD
Phone 0041442551111
Email alexander.navarini@usz.ch
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A phase 4 multicenter, randomized, placebo-controlled Study evaluating the Effect of Apremilast on Pruritus and Quality of Life of Patients with moderate-to-severe Scalp Psoriasis


Description:

The scalp is the most frequently affected body region in psoriasis. Scalp Psoriasis can impair the quality of life greatly due to pruritus. This is however not usually investigated as a primary outcome of treatments.

This study will investigate the effects of apremilast on the pruritus and quality of life and other patient reported outcomes in patients with scalp psoriasis.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 90
Est. completion date June 2020
Est. primary completion date December 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria:

1. Adult (>18yrs);

2. Signed informed consent

3. Clinical diagnosis of chronic plaque psoriasis for at least 3 months as determined by the subject's medical history and confirmation of diagnosis through physical examination by the Investigator;

4. Psoriatic lesions with DLQI >10 and involvement of >20% of the scalp and pruritus with a VAS score of > 50 (0-100);

5. Candidate for systemic therapy;

6. Females who are of child-bearing potential should be practicing birth control throughout the study and for 70 days after the last dose of study drug;

7. Subject is judged to be in good health as determined by the Investigator based upon the results of medical history, laboratory profile and physical examination.

8. Creatinine < 80 umol/l at Inclusion

Exclusion criteria:

1. Erythrodermic Ps, medication-induced or medication-exacerbated Ps or new onset guttate Ps or other skin conditions at the time of the screening visit (e.g. eczema) that would interfere with evaluations of the effect of the investigational product on Ps;

2. Use of any anti-psoriatic therapy last administered less than 4 weeks of start of study drug such as

1. Three months or 5 PK half-lives, whichever is longer, for biologics tumor necrosis factor (TNF) antagonists, interleukin (IL) 12/23/17 inhibitors or other biologic drugs

2. 4 weeks for immunosuppressive / -modulating drugs including cyclosporine A, methotrexate, azathioprine, mycophenolate mofetil, fumaric acid esters, retinoids, JAK inhibitors, corticosteroids, any other experimental drug, etc.

3. Topical medications (eg. Corticosteroids) except coal tar shampoo, and/or salicylic acid scalp preparations on scalp lesions.

4. 4 weeks for phototherapy (ie, UVB, PUVA).

3. Infection(s) requiring treatment with intravenous (IV) anti-infectives within 30 days prior to the Baseline visit or oral anti-infectives within 14 days prior to the Baseline visit;

4. Positive serology for hepatitis B, hepatitis C, HIV indicating acute or chronic infection;

5. Chronic recurring bacterial infections or active TB;

6. Positive pregnancy test at Screening or at the Baseline visit;

7. Female subjects who are pregnant or breast-feeding or considering becoming pregnant during the study;

8. History of clinically significant alcohol or drug abuse in the last 12 months;

9. Known hypersensitivity to the excipients of Otezla® as stated in the label;

10. Subject is considered by the Investigator, for any reason, to be an unsuitable candidate for the study.

11. Prior history of suicide attempt at any time in the subject's life time prior to signing the informed consent and randomization, or major psychiatric illness requiring hospitalization within the last 3 years prior to signing the informed consent.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Apremilast 30mg
Anti-psoriatic drug
Placebo Oral Tablet
Indistinguishable tablets not containing apremilast, Placebo Oral Tablet

Locations

Country Name City State
Switzerland Inselspital Bern
Switzerland CHUV Lausanne
Switzerland KSSG Saint Gallen SG
Switzerland Department of Dermatology, University Hospital Zurich Zurich

Sponsors (1)

Lead Sponsor Collaborator
University of Zurich

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Scalp VAS Pruritus assessment Pruritus VAS Scale (0 - 100) Weeks 16
Secondary Scalp VAS Pruritus assessment Pruritus VAS Scale (0 - 100) Weeks 0, 4, 32, 52
Secondary % BSA Body surface area Weeks 0, 4, 16, 32, 52
Secondary % BSA of scalp Body surface area of scalp Weeks 0, 4, 16, 32, 52
Secondary PrecisePASI Psoriasis Area and Severity Index, modified to measure in percentages Weeks 0, 4, 16, 32, 52
Secondary PGA Physicians Global Assessment (0 - 5) Weeks 0, 4, 16, 32, 52
Secondary Scalp-PGA Physicians Global Assessment of the Scalp (0 - 5) Weeks 0, 4, 16, 32, 52
Secondary DLQI Skin related Quality of life (0 to 30) Weeks 0, 4, 16, 32, 52
Secondary Scalpdex 23 items related to scalp symptoms Weeks 0, 4, 16, 32, 52
Secondary PSSI Psoriasis score measuring intensity on the scalp Weeks 0, 4, 16, 32, 52
Secondary VAS pruritus assessment Pruritus VAS Scale (0 - 100) Weeks 0, 4, 16, 32, 52
Secondary EQ-5D Health-related Quality of Life Instrument Weeks 0, 4, 16, 32, 52
See also
  Status Clinical Trial Phase
Completed NCT03669757 - Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamic Effect of Different Concentrations of a New Anti-inflammatory Substance in Subjects With Chronic Plaque Psoriasis Phase 1
Completed NCT03614078 - A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis Phase 2
Completed NCT03584360 - Role of Topical Treatments in the Modulation of Skin Microbiome in Psoriatic Skin Phase 2
Recruiting NCT04994951 - Pilot Study of Traditional Chinese Medicine (Qing-Re-Liang-Xue Decoction) as Complementary Medicine for Psoriasis Vulgaris of Blood-heat Syndrome. Phase 2
Completed NCT02888236 - LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris Phase 2
Completed NCT02533973 - Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population Phase 4
Completed NCT02193815 - A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis Phase 1
Completed NCT01946386 - A Vasoconstriction Study With LEO 90100 Phase 1
Completed NCT02004847 - Blue Light for Treating Psoriasis Vulgaris N/A
Recruiting NCT01443338 - Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Psoriasis Vulgaris - CHINA201002016-2 Phase 4
Completed NCT01188928 - LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs) Phase 3
Completed NCT00764751 - Efficacy and Safety of LEO 19123 Cream in the Treatment of Psoriasis Vulgaris Phase 2
Completed NCT00236171 - Evaluation of Topical Antipsoriatics in the Psoriasis Plaque Test N/A
Completed NCT04541329 - Predicting Inflammatory Skin Disease Response to IL-23 Blockade Phase 4
Completed NCT06064084 - Incretin Effect in Patients With Psoriasis and Controls
Not yet recruiting NCT06398106 - Proactive TDM Versus Standard Use of Biologics in Psoriasis Phase 4
Recruiting NCT05390515 - Psoriatic Immune Response to Tildrakizumab Phase 4
Recruiting NCT05892640 - Low-Salt Diet Effect on Th17-Mediated Inflammation and Vascular Reactivity in Psoriasis N/A
Recruiting NCT04950218 - The Psoriasis Echo Study
Completed NCT05184348 - Plexin B2 Gene Expression and Polymorphisms in Psoriasis Phase 1